Comerica Bank Sells 10,288 Shares of Haemonetics Co. (NYSE:HAE)

Comerica Bank decreased its holdings in shares of Haemonetics Co. (NYSE:HAEGet Rating) by 30.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,160 shares of the medical instruments supplier’s stock after selling 10,288 shares during the period. Comerica Bank’s holdings in Haemonetics were worth $1,860,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wipfli Financial Advisors LLC purchased a new stake in shares of Haemonetics in the 3rd quarter valued at about $25,000. Eagle Bay Advisors LLC raised its stake in Haemonetics by 155.1% in the second quarter. Eagle Bay Advisors LLC now owns 653 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. FinTrust Capital Advisors LLC bought a new stake in Haemonetics during the third quarter valued at approximately $60,000. SeaCrest Wealth Management LLC purchased a new position in Haemonetics in the 2nd quarter worth approximately $65,000. Finally, USA Financial Portformulas Corp bought a new position in shares of Haemonetics in the 3rd quarter worth $91,000.

Haemonetics Stock Performance

Shares of HAE stock opened at $89.32 on Friday. The company has a market capitalization of $4.52 billion, a P/E ratio of 53.81 and a beta of 0.39. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $89.34. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.76 and a current ratio of 2.73. The stock has a 50 day moving average price of $81.12 and a two-hundred day moving average price of $76.72.

Haemonetics (NYSE:HAEGet Rating) last posted its quarterly earnings results on Monday, November 7th. The medical instruments supplier reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.70 by $0.13. The company had revenue of $297.49 million during the quarter, compared to analyst estimates of $273.92 million. Haemonetics had a net margin of 7.94% and a return on equity of 20.05%. Analysts expect that Haemonetics Co. will post 2.87 earnings per share for the current year.

Analyst Upgrades and Downgrades

HAE has been the subject of several research reports. JMP Securities upped their target price on shares of Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 8th. Barrington Research increased their price objective on Haemonetics from $88.00 to $94.00 and gave the company an “outperform” rating in a research report on Tuesday, November 8th. Raymond James raised their price objective on Haemonetics from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Mizuho upped their target price on Haemonetics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, November 8th. Finally, Morgan Stanley decreased their price target on shares of Haemonetics from $90.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Friday, January 6th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $95.83.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Featured Articles

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.